Form 4: ARS Pharmaceuticals CFO Kathleen Scott Executes Stock Option and Sells Shares

Kathleen Scott, CFO of ARS Pharmaceuticals, exercised stock options and sold 50,000 shares of common stock on May 20, 2025.

Summary

• Kathleen Scott, the Chief Financial Officer of ARS Pharmaceuticals, Inc., executed a transaction involving the company's stock on May 20, 2025.
• Scott exercised a stock option to purchase 50,000 shares at a price of $1.50 per share.
• Simultaneously, Scott sold 50,000 shares of common stock at a weighted average price of $14.1033, with prices ranging from $14.10 to $14.115.
• Following these transactions, Scott directly owns 57,424 shares and indirectly owns 8,250 shares through the Scott 2008 Trust Dated 3/28/08.
• Scott also directly owns 752,330 derivative securities in the form of stock options.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of insider trading activity. The CFO exercised options and sold shares, which could be interpreted in various ways depending on the context and individual investor perspective.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It provides transparency into the trading activities of company executives, which is important for investors to assess management's confidence in the company's prospects.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders.
• The information disclosed is consistent with regulatory requirements for reporting changes in beneficial ownership.

Stakeholder Impact

• Shareholders may interpret the CFO's stock sale as a lack of confidence in the company, or simply as a personal financial decision.
• The transactions have no immediate impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

ARS Pharmaceuticals, Kathleen Scott, stock options, Form 4, insider trading, SPRY, CFO, stock sale, equity securities